AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Gentian Diagnostics ASA

Quarterly Report Nov 7, 2019

3604_rns_2019-11-07_fb17bf36-89b4-456c-8d35-6a6ccb0eefd2.html

Quarterly Report

Open in Viewer

Opens in native device viewer

Third quarter financial report

Third quarter financial report

Moss, 7 November 2019

Gentian Diagnostics AS announces its results for the third quarter of 2019. The highlights include:

• Record sales revenues of MNOK 13.1 in 3Q19, up from MNOK 10.4 in 3Q18, totaling a 26 % growth YOY

• Record sales revenue for the first nine months of MNOK 33.9 representing 18% growth compared to

the same period of 2018

• In July, Gentian and Beckman Coulter, one of the top 5 global diagnostics companies, prolongated

their partnership agreement for Cystatin C by 6 years

• In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche

Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG

Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.

For further information, please contact:

Hilja Ibert

CEO, Gentian Diagnostics

E-mail: [email protected]

Cell Phone: +47 919 05 242

Njaal Kind

CFO, Gentian Diagnostics

E-mail: [email protected]

Cell Phone. +47 919 06 525

Talk to a Data Expert

Have a question? We'll get back to you promptly.